{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:33:15Z","timestamp":1789842795004,"version":"4.0.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,12]]},"DOI":"10.7759\/cureus.77331","type":"journal-article","created":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T20:05:46Z","timestamp":1736712346000},"source":"Crossref","is-referenced-by-count":2,"title":["Immune Checkpoint Inhibitor-Induced Hepatitis: A Case Report of Challenging Management"],"prefix":"10.7759","author":[{"given":"In\u00eas","family":"Soldin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ortig\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100719","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji L","year":"2023","unstructured":"Hountondji L, Ferreira De Matos C, Leboss\u00e9 F, et al.. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Rep. 2023, 5:100719. 10.1016\/j.jhepr.2023.100719","journal-title":"JHEP Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000509953","article-title":"Pembrolizumab-induced delayed-onset hepatitis","volume":"14","author":"Kanaoka K","year":"2020","unstructured":"Kanaoka K, Moriizumi K, Okada H, Iwahashi K, Tsuji H, Yasuoka H, Minami S. Pembrolizumab-induced delayed-onset hepatitis. Case Rep Gastroenterol. 2020, 14:586-92. 10.1159\/000509953","journal-title":"Case Rep Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2591-18","article-title":"Cholestatic liver injury induced by pembrolizumab in a patient with lung adenocarcinoma","volume":"58","author":"Kurokawa K","year":"2019","unstructured":"Kurokawa K, Hara M, Iwakami SI, et al.. Cholestatic liver injury induced by pembrolizumab in a patient with lung adenocarcinoma. Intern Med. 2019, 58:3283-7. 10.2169\/internalmedicine.2591-18","journal-title":"Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama T","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al.. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020, 26:353-65. 10.3748\/wjg.v26.i3.353","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001322","article-title":"When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report","volume":"8","author":"Ziogas DC","year":"2020","unstructured":"Ziogas DC, Gkoufa A, Cholongitas E, Diamantopoulos P, Anastasopoulou A, Ascierto PA, Gogas H. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. J Immunother Cancer. 2020, 8:10.1136\/jitc-2020-001322","journal-title":"J Immunother Cancer"},{"key":"ref8","article-title":"Pembrolizumab","year":"2012","unstructured":"Pembrolizumab. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2012."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00105","article-title":"Immunotherapy-induced hepatotoxicity: a review","volume":"10","author":"Da Cunha T","year":"2022","unstructured":"Da Cunha T, Wu GY, Vaziri H. Immunotherapy-induced hepatotoxicity: a review. J Clin Transl Hepatol. 2022, 10:1194-204. 10.14218\/JCTH.2022.00105","journal-title":"J Clin Transl Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/332691-immune-checkpoint-inhibitor-induced-hepatitis-a-case-report-of-challenging-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T20:05:47Z","timestamp":1736712347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/332691-immune-checkpoint-inhibitor-induced-hepatitis-a-case-report-of-challenging-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,12]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.77331","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,12]]}}}